Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study

Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study

Objective. To evaluate the therapeutic effectiveness of reducing the infliximab dose interval to 6 weeks in spondyloarthropathy patients not responding to 5 mg/kg every 8 weeks. Methods. After 30 weeks of infliximab therapy, 25 patients were classified as responders [Bath Ankylosing Spondylitis Acti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2005-12, Vol.44 (12), p.1555-1558
Hauptverfasser: Collantes-Estevez, E., Muñoz-Villanueva, M. C., Zarco, P., Torre-Alonso, J. C., Gratacós, J., González, C., Sanmartí, R., Cañete, J. D.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Ankylosing spondylitis
Anti-tumour necrosis factor-α
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - therapeutic use
Biological and medical sciences
Blood Sedimentation
C-Reactive Protein - metabolism
Diseases of the osteoarticular system
Drug Administration Schedule
Female
Humans
Immunomodulators
Inflammatory joint diseases
Infliximab
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prospective Studies
Severity of Illness Index
Spondylarthropathies - drug therapy
Spondyloarthropathies
Treatment Failure
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective. To evaluate the therapeutic effectiveness of reducing the infliximab dose interval to 6 weeks in spondyloarthropathy patients not responding to 5 mg/kg every 8 weeks. Methods. After 30 weeks of infliximab therapy, 25 patients were classified as responders [Bath Ankylosing Spondylitis Activity Index (BASDAI)
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/kei085